RxDoctor Payments Data

Hermes Milanes, MD

Surgery · Miami, FLNPI 1992969745

Payments from drug & device makers

$3,039in general payments, 2019–2025

Across 108 payments — averaging $28.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Boehringer Ingelheim$665
  • Lilly USA, LLC$190
  • Amgen$124
  • Novo Nordisk$46
  • Merck$35
  • plus $127 from 5 others

What the payments were for

  • Food & beverage$3,039100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,039 in reported general payments places this provider in the 50th percentile of 1,569 surgery providers in Florida.

See all surgery providers in Florida

Medicare billing

Part B allowed, 2024
$95,372
Medicare patients
86
Services billed
1,055

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin114$134,068
OzempicSemaglutide94$90,578
TrulicityDulaglutide64$64,117
FarxigaDapagliflozin Propanediol49$56,760
JanuviaSitagliptin Phosphate24$32,200
MounjaroTirzepatide26$29,477
EliquisApixaban31$28,923
XareltoRivaroxaban20$16,379
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$12,691
LinzessLinaclotide15$8,101
Breo ElliptaFluticasone/Vilanterol12$4,986
Gabapentin150$1,559
Omega-3 Acid Ethyl Esters12$1,276
Famotidine91$1,159
Atorvastatin Calcium142$746

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$665$134,068114 claims
Lilly USA, LLCTrulicity, Mounjaro$190$93,59490 claims
Novo NordiskOzempic$46$90,57894 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,851$69,45169 claims
MerckJanuvia$35$32,20024 claims
AbbVieLinzess$21$8,10115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,569 surgery providers in Florida.

Other surgery in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →